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Zhang, Rong, Thad E. Wilson, Sarah Witkowski, Jian Cui,
Craig G. Crandall, and Benjamin D. Levine. Inhibition of nitric
oxide synthase does not alter dynamic cerebral autoregulation in
humans. Am J Physiol Heart Circ Physiol 286: H863–H869, 2004.
First published November 6, 2003; 10.1152/ajpheart.00373.2003.—
The aim of this study was to determine whether inhibition of nitric
oxide synthase (NOS) alters dynamic cerebral autoregulation in humans. Beat-to-beat blood pressure (BP) and cerebral blood flow
(CBF) velocity (transcranial Doppler) were measured in eight healthy
subjects in the supine position and during 60° head-up tilt (HUT).
NOS was inhibited by intravenous NG-monomethyl-L-arginine (LNMMA) infusion. Dynamic cerebral autoregulation was quantified by
transfer function analysis of beat-to-beat changes in BP and CBF
velocity. Pressor effects of L-NMMA on cerebral hemodynamics were
compared with those of phenylephrine infusion. In the supine position, L-NMMA increased mean BP from 83 ⫾ 3 to 94 ⫾ 3 mmHg
(P ⬍ 0.01). However, CBF velocity remained unchanged. Consequently, cerebrovascular resistance index (CVRI) increased by 15%
(P ⬍ 0.05). BP and CBF velocity variability and transfer function gain
at the low frequencies of 0.07–0.20 Hz did not change with L-NMMA
infusion. Similar changes in mean BP, CBF velocity, and CVRI were
observed after phenylephrine infusion, suggesting that increase in
CVRI after L-NMMA was mediated myogenically by increase in
arterial pressure rather than a direct effect of cerebrovascular NOS
inhibition. During baseline tilt without L-NMMA, steady-state BP
increased and CBF velocity decreased. BP and CBF velocity variability at low frequencies increased in parallel by 277% and 217%,
respectively (P ⬍ 0.05). However, transfer function gain remained
unchanged. During tilt with L-NMMA, changes in steady-state hemodynamics and BP and CBF velocity variability as well as transfer gain
and phase were similar to those without L-NMMA. These data suggest
that inhibition of tonic production of NO does not appear to alter
dynamic cerebral autoregulation in humans.
cerebral blood flow; head-up tilt; transcranial Doppler

of nitric oxide synthase (NOS) increases
vasomotor tone and arterial pressure in humans under steadystate conditions (19). In addition, inhibition of NOS with
L-arginine analogs, or in NOS gene-deficient mice, provokes
large beat-to-beat blood pressure fluctuations at frequencies
between 0.1 and 0.6 Hz (22, 23). These data suggest that
besides the steady-state pressor effects, NO may also modulate
vasomotor tone, dynamically responding to transient changes
in blood pressure and/or flow, and thus may contribute to the
stability of the systemic circulation (23). However, whether
this function is physiologically significant in humans, and
especially in the cerebral circulation, is unknown.
SYSTEMIC INHIBITION
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In humans, cerebral blood flow (CBF) velocity in the basal
cerebral arteries fluctuates spontaneously, similar to arterial
pressure (8, 14, 16, 36). In addition, the cerebral vasculature
appears to buffer changes in CBF induced by transient changes
in arterial pressure under dynamic conditions (1, 16, 36). This
ability of the cerebrovascular bed has been referred to as
“dynamic cerebral autoregulation.” In contrast, the traditional
concept of cerebral autoregulation, which emphasizes a relatively constant CBF despite large changes in arterial pressure
under steady-state conditions, has been referred to as “static
cerebral autoregulation” (17).
Thus, theoretically, if tonic production of NO plays an
obligatory role in buffering changes in CBF induced by transient changes in pressure, dynamic cerebral autoregulation
would be impaired by NOS inhibition. A recent study of
dynamic cerebral autoregulation during acute hypotension induced by thigh cuff deflation suggested the presence of this
regulatory mechanism (34).
To extend these previous observations, the present study
examined dynamic cerebral autoregulation from spontaneous
fluctuations in arterial pressure and CBF velocity. NOS activity
was inhibited by intravenous infusion of NG-monomethyl-Larginine (L-NMMA). Dynamic cerebral autoregulation was
quantified by transfer function analysis of beat-to-beat changes
in arterial pressure and CBF velocity (8, 14, 16, 21, 36). We
hypothesized that inhibition of tonic production of NO would
alter dynamic cerebral autoregulation in humans.
METHODS

Eight healthy subjects (6 men, 2 women) with mean age of 31 ⫾
3 yr, mean height of 173 ⫾ 4 cm, and mean weight of 73 ⫾ 4 kg
voluntarily participated in this study. No subject smoked or had
known medical problems. Subjects were screened carefully with a
medical history and a physical examination with 12-lead ECG. All
subjects signed an informed consent form approved by the Institutional Review Boards of the University of Texas Southwestern Medical Center and Presbyterian Hospital of Dallas.
Beat-to-beat arterial pressure was measured with finger photoplethysmography (Finapres). The pressure transducer was positioned
carefully at the heart level both in the supine position and during 60°
head-up tilt and corroborated with the measurement of brachial artery
pressure with a sphygmomanometer (Suntech). Beat-to-beat pressure
recordings were used to quantify pressure variability. Intermittent
brachial pressure recordings were used to quantify steady-state pressure and to estimate both systemic and cerebrovascular resistance.
CBF velocity was measured in the middle cerebral artery (MCA)
by transcranial Doppler ultrasonography. The optimal Doppler signal
was obtained according to standard techniques with the sample
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volume adjusted to the proximal segment of the MCA. A 2-MHz
probe (Multiflow, DWL) was placed over the subject’s temporal
window and fixed at a constant angle with a probe holder custom
made to fit each subject’s facial bone structure. This approach ensured
that the exact same probe angle, the same segment of the MCA, and
the same instrument settings were used in all repeat studies (6).
Heart rate was monitored continuously by ECG. Respiratory excursions were monitored via a piezoelectric transducer (Pneumotrace,
UFI; Morro Bay, CA). End-tidal CO2 (ETCO2) was measured with a
nasal cannula interfaced with a mass spectrometer (Marquette Electronics). Cardiac output was measured by using a standard foreign gas
rebreathing technique with acetylene as the soluble and helium as the
insoluble gas (28). Adequate mixing of the rebreathing gas in the lung
was confirmed by a constant level of helium in all cases. Stroke
volume was calculated as cardiac output divided by the heart rate
during rebreathing. Total peripheral vascular resistance was calculated
as mean arterial pressure divided by cardiac output.
Experimental protocols. All experiments were performed in the
morning at least 2 h after a light breakfast. The subjects were asked to
refrain from heavy exercise and caffeinated or alcoholic beverages for
at least 24 h before the tests. After at least 30 min of supine rest,
cardiac output was measured, followed by a 6-min period of data
collection during which the subject breathed spontaneously. The
subject was then tilted passively to the 60° head-up position. After 2
min for stabilization, 6 min of data was collected, followed by a
measurement of cardiac output during tilt. The subject was then
returned to the supine position for a recovery period of ⬃45 min.
After the recovery, NOS was inhibited by intravenous infusion of
L-NMMA with a loading dose of 5 mg/kg for 15 min, followed by a
maintenance dose of 50 g䡠kg⫺1 䡠min⫺1 throughout the duration of
the ⬃45-min study. Previous work demonstrated stable blood concentrations of L-NMMA and sustained inhibition of NOS with this
regimen in healthy humans (15, 20). After 30 min of L-NMMA
infusion, two measurements of cardiac output were obtained and
averaged. A 6-min period of data collection followed in the supine
position. Head-up tilt and data collection were then repeated in the
presence of L-NMMA as outlined above.
On a separate day at least 1 mo from the experiments with
L-NMMA, low-dose phenylephrine (0.5 g䡠kg⫺1 䡠min⫺1), an ␣1agonist with no direct cerebral vasoactive effects (4), was infused in
the same group of subjects to account for the pressor effect of
L-NMMA on cerebral hemodynamics in the supine position. Data
collection was conducted before and after 5 min of phenylephrine
infusion, when the increases in arterial pressure were stabilized at a
level equivalent to those during L-NMMA infusion.
Data analysis. Steady-state arterial pressure was obtained from the
average of at least three measurements of brachial pressure under each
experimental condition. Heart rate, CBF velocity, and ETCO2 were
obtained from the average of the 6-min data segments. A “cerebrovascular resistance index (CVRI)” in the supine position was calculated by dividing mean blood pressure by mean CBF velocity to
estimate relative changes in cerebrovascular resistance (1). It should
be noted that although the hydrostatic component of arterial pressure
at the head level must be reduced during head-up tilt relative to the
supine position (8), whether intracranial and cerebral venous pressure
are reduced commensurately is not completely understood (18). Given
these uncertainties, changes in cerebrovascular resistance during tilt
were not estimated in the present study. However, we have considered
that the magnitude of beat-to-beat changes in mean arterial pressure
during head-up tilt should reflect that of changes in cerebral perfusion
pressure (8, 21, 35).
The magnitude of beat-to-beat changes in mean arterial pressure
and CBF velocity was quantified by Fourier spectral analysis. The
transfer function between these variables was calculated to assess
dynamic cerebral autoregulation as described previously (36). Briefly,
AJP-Heart Circ Physiol • VOL

the estimates of transfer function gain were used to quantify the ability
of the cerebrovascular bed to buffer changes in CBF velocity induced
by transient changes in arterial pressure at different frequencies. The
phase spectrum was estimated to reflect the temporal relationship
between these variables. In addition, to account for the effects of
steady-state changes in arterial pressure and CBF velocity on the
transfer function gain estimation in the supine position, a normalized
transfer function gain was derived as a product of the estimated
transfer function gain and the CVRI under these conditions (21).
Finally, the coherence function between changes in arterial pressure
and CBF velocity was estimated to assess the linear correlation
between these variables.
Spectral power of arterial pressure and CBF velocity were calculated in the very low (0.02–0.07 Hz), low (LF, 0.07–0.20 Hz), and
high (HF, 0.20–0.35 Hz) frequency ranges. Mean values of transfer
function gain and phase were calculated in the LF and HF ranges. The
selection of these frequencies was based on estimates of coherence
function ⬎0.5 and the unique features of the dynamic pressure-CBF
velocity relationship in these ranges as described previously (8, 36).
Statistics. The data were examined by using a two-way repeatedmeasures ANOVA with tilt and L-NMMA as experimental factors
(SigmaStat, SPSS). When statistically significant differences were
observed, a further post hoc comparison was conducted by using the
Student-Newman method. Comparisons between the two baselines
before L-NMMA and phenylephrine infusion were conducted by using
a paired test. Because no significant change was observed between the
two baseline measurements, comparisons between baseline (before
L-NMMA infusion), L-NMMA infusion, and phenylephrine infusion
were performed by using one-way repeated-measures ANOVA. Data
are expressed as means ⫾ SE. The significance level was set at P ⬍
0.05.
RESULTS

Steady-state hemodynamics. In the supine position, infusion
of L-NMMA increased mean arterial pressure significantly by
13%. However, CBF velocity remained unchanged. Consequently, CVRI increased significantly by 15% (Fig. 1, Table 1).
Cardiac output and stroke volume did not change, and there
was a trend toward an increase in total peripheral vascular
resistance (TPR) (P ⫽ 0.07) (Table 1). Of note, changes in
blood pressure, CBF velocity, and CVRI after L-NMMA were
virtually identical to those with phenylephrine infusion
(Fig. 1).
During baseline tilt without L-NMMA, mean arterial pressure increased because of an increase in diastolic pressure.
CBF velocity decreased, associated with a reduction in ETCO2
(Table 1). Cardiac output and stroke volume were reduced by
17% and 38%, respectively, associated with a significant increase in TPR by 42% (Table 1). Head-up tilt in the presence
of L-NMMA induced changes in both systemic and cerebral
hemodynamics similar to those during tilt without L-NMMA
(Table 1).
Beat-to-beat data analysis. In the supine position, infusion
of L-NMMA did not change the spectral power of arterial
pressure and CBF velocity variability at all frequencies (Fig. 2,
Table 2), nor did it change the transfer function gain at the low
frequencies. However, transfer function gain at the high frequencies decreased significantly by 19% (Fig. 3, Table 2). The
normalized gain remained unchanged (LF: 1.42 ⫾ 0.16 vs.
1.22 ⫾ 0.13, P ⫽ 0.34; HF: 1.37 ⫾ 0.11 vs. 1.46 ⫾ 0.09, P ⫽
0.44). There was a trend toward decreases in phase at the low
frequencies after L-NMMA (P ⫽ 0.13, power ⫽ 0.51; Fig. 3,
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Fig. 1. Steady-state mean blood pressure (MBP; A), cerebral blood flow
velocity (CBFV; B), and “cerebrovascular resistance index” (CVRI ⫽ MBP/
CBFV, units ⫽ mmHg䡠s䡠cm⫺1; C) obtained in the supine position at baseline,
after NG-monomethyl-L-arginine (L-NMMA) infusion, and after phenylephrine
infusion. Values are means ⫾ SE; n ⫽ 8. *P ⬍ 0.05 compared with baseline.

Table 2). Of note, no significant difference in transfer function
gain, phase, or coherence was observed after phenylephrine
infusion compared with those after L-NMMA (Fig. 4, Table 2).
During baseline tilt without L-NMMA, spectral power of
arterial pressure and CBF velocity variability increased substantially at the low and high frequencies (Fig. 2, Table 2).
Transfer function gain remained unchanged at the low frequencies, whereas it decreased significantly by 16% at the high
frequencies (Fig. 3, Table 2). Similarly, there was a trend
toward decreases in phase at the low frequencies during tilt
associated with the significant increases in arterial pressure
(P ⫽ 0.06, power ⫽ 0.72; Fig. 3, Table 2). Head-up tilt in the
presence of L-NMMA induced changes in arterial pressure and
CBF velocity variability as well as transfer function gain and
phase similar to those during tilt without L-NMMA (Figs. 2 and
3, Table 2).
DISCUSSION

The primary new findings of the present study are twofold.
1) We demonstrated for the first time that systemic inhibition
of NOS does not alter CBF velocity variability even when the
AJP-Heart Circ Physiol • VOL

magnitude of these oscillations is significantly enhanced during
head-up tilt. 2) Transfer function gain between beat-to-beat
changes in arterial pressure and CBF velocity at the low
frequencies (⬍0.2 Hz) remained unchanged after L-NMMA
infusion in the supine position and did not change during
head-up tilt, although there was a trend toward decreases in
phase at the low frequencies after L-NMMA in both positions,
associated with the increases in arterial pressure. These data, in
contrast to our hypothesis, suggest that inhibition of tonic
production of NO does not alter dynamic cerebral autoregulation in humans.
CBF and NO. The role of NO in modulating the cerebral
circulation has been studied extensively (5). Most studies in
animals showed that inhibition of NOS reduces resting CBF
and may attenuate CBF responses to hypercapnic stimuli (10,
30). These findings provide evidence that tonic production of
NO (either endothelial or neuronal) modulates cerebral vasomotor tone. However, the data obtained in humans are rather
limited and inconsistent. For example, in healthy subjects after
intravenous bolus injection of L-NMMA, internal carotid CBF,
measured by Doppler ultrasonography, was reduced significantly by 15% despite significant increases in arterial pressure
(32). These findings were supported by a follow-up study from
the same investigators using positron emission tomography to
measure global CBF after L-NMMA (33). However, resting
CBF after intravenous infusion of L-NMMA remained unchanged when measured by phase-contrast magnetic resonance
imaging (29). Moreover, intracarotid infusion of nitroprusside
(an exogenous NO donor) did not increase CBF in patients
undergoing cerebral angiography, whereas infusion of
L-NMMA reduced CBF by 20% (12, 13). The exact mechanism(s) underlying these discrepancies is difficult to delineate
given the limitations of studies in humans regarding the temporal nature and extent of NOS inhibition in the cerebral
circulation and the different methods used for CBF measurements (27).
In the present study, we observed that CBF velocity in the
MCA remained unchanged after L-NMMA infusion, associated
with significant increases in arterial pressure. In addition, we

Table 1. Steady-state hemodynamics
Control

HR, bpm
SBP, mmHg
DBP, mmHg
PBP, mmHg
MBP, mmHg
CBFV, cm/s
CO, liter
SV, ml
TPR, dyn䡠s䡠cm5
ETCO2, mmHg

L-NMMA

Supine

Tilt

Supine

Tilt

60⫾4
112⫾4
68⫾3
44⫾3
83⫾3
69⫾5
7.27⫾0.52
102⫾7
916⫾43
38⫾1

89⫾4*
119⫾4
82⫾3*
37⫾3*
95⫾3*
59⫾5*
6.05⫾0.33*
63⫾4*
1,300⫾79*
35⫾1*

57⫾5
122⫾3†
80⫾3†
42⫾2
94⫾3†
69⫾5
7.54⫾0.76
113⫾8
1,033⫾77
37⫾1

84⫾4*
125⫾4†
91⫾3*†
34⫾2*
102⫾3*†
61⫾4*
6.37⫾0.45
69⫾6*
1,302⫾76
35⫾1*

Values are means ⫾ SE; n ⫽ 8 subjects. HR, heart rate; SBP, systolic
pressure; DBP, diastolic pressure; PBP, pulse pressure; CBFV, cerebral blood
flow velocity; CO, cardiac output; SV, stroke volume; TPR, total peripheral
vascular resistance; ETCO2, end-tidal CO2. *P ⬍ 0.05, between supine and tilt
under the same NG-monomethyl-L-arginine (L-NMMA) conditions; †P ⬍ 0.05,
before and after L-NMMA in the same body position.
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Fig. 2. Group-averaged spectra of MBP and CBFV variability
in the supine position (A) and during tilt (B) before (solid line)
and after (dotted line) L-NMMA.

found that with the same pressor effects of phenylephrine
infusion, steady-state CBF velocity also remained unchanged
and CVRI increased to the same degree as that with L-NMMA.
These data suggest that the increase in CVRI after L-NMMA
was mediated myogenically by an increase in arterial pressure
(autoregulatory responses) rather than a direct effect of cerebrovascular NOS inhibition (17). Consequently, the absence of
changes in CBF velocity observed in the present study may
indicate the lack of change in resting CBF after L-NMMA (29).
However, we cannot exclude the possibility that if infusion of
L-NMMA induced significant vasoconstriction in the MCA as
well as in the downstream resistance vessels of the cerebral
circulation a true reduction of CBF may have been underestimated by the measurement of CBF velocity in the present
study (32).
Cerebral autoregulation and NO. Under steady-state conditions, whether NO plays a role in static cerebral autoregulation
is uncertain (11, 24, 25, 31). Studies in rats using laser Doppler
flowmetry to measure CBF suggest that NO is an important

mediator of cerebral vasodilation during hemorrhagic hypotension and that NOS inhibition shifts the lower limit of the
autoregulatory curve to higher pressures (11, 26). However,
measurement of CBF with either autoradiography (24) or the
133
Xe clearance method failed to support this conclusion (31).
In addition, static cerebral autoregulation was not altered by
intracarotid infusion of L-NMMA in primates (25).
Under dynamic conditions, the magnitude of oscillations in
CBF and CBF velocity in rats was enhanced substantially by
intravenous infusion of the NOS inhibitor N-nitro-L-arginine
methyl ester (3). These data suggest that tonic production of
NO may attenuate oscillations in CBF induced by spontaneous
changes in arterial pressure. Moreover, dynamic cerebral autoregulation in humans during acute hypotension induced by
thigh cuff deflation was impaired after intravenous bolus injection of L-NMMA (34). These data, similar to the observations in peripheral vascular beds (23), indicate that NO may
modulate cerebral vasomotor tone dynamically in response to
transient changes in blood pressure and/or flow.

Table 2. Spectral analysis of blood pressure and CBFV variability
Control

MBPVLF, mmHg2
MBPLF, mmHg2
MBPHF, mmHg2
CBFVVLF, (cm/s)2
CBFVLF, (cm/s)2
CBFVHF, (cm/s)2
GainLF, cm䡠s䡠mmHg⫺1
GainHF, cm䡠s䡠mmHg⫺1
PhaseLF, radians
PhaseHF, radians
CoherenceLF, units
CoherenceHF, units

Phenylephrine

L-NMMA

Supine

Tilt

Supine

Supine

Tilt

6.63⫾2.07
3.47⫾1.30
0.14⫾0.04
8.75⫾2.22
3.44⫾0.89
0.31⫾0.05
1.00⫾0.09
1.22⫾0.09
0.76⫾0.07
0.22⫾0.09
0.65⫾0.07
0.60⫾0.04

3.85⫾0.81
13.09⫾3.89*
1.91⫾0.71*
4.99⫾1.34
10.90⫾3.01*
2.10⫾0.59*
0.96⫾0.05
1.03⫾0.07*
0.55⫾0.04
0.23⫾0.04
0.77⫾0.03
0.76⫾0.02*

4.39⫾1.73
1.55⫾0.57
0.25⫾0.09
5.46⫾1.69
2.13⫾0.85
0.51⫾0.22
0.98⫾0.06
1.14⫾0.09
0.68⫾0.06
0.22⫾0.16
0.56⫾0.07
0.60⫾0.05

4.90⫾1.38
1.61⫾0.43
0.17⫾0.05
6.72⫾2.44
1.81⫾0.37
0.24⫾0.05
1.00⫾0.08
0.99⫾0.08†
0.59⫾0.08
0.21⫾0.10
0.54⫾0.07
0.56⫾0.05

5.53⫾0.94
11.44⫾3.03*
1.33⫾0.39
4.16⫾0.88
8.76⫾2.58*
1.46⫾0.29*
0.91⫾0.07
0.95⫾0.07
0.49⫾0.06
0.21⫾0.05
0.70⫾0.06*
0.68⫾0.06

Values are means ⫾ SE; n ⫽ 8 subjects. VLF, very low frequency; LF, low frequency; HF, high frequency. *P ⬍ 0.05, between supine and tilt under the
same L-NMMA conditions; †P ⬍ 0.05, before and after L-NMMA in the same body position.
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Fig. 3. Group-averaged transfer function gain, phase, and
coherence function in the supine position (A) and during tilt (B)
before (solid line) and after (dotted line) L-NMMA.

However, in the present study, we found that both arterial
pressure and CBF velocity variability did not change after
L-NMMA even when the magnitude of these oscillations was
enhanced substantially during head-up tilt. In addition, transfer
function gain between these variables at low frequencies
(where autoregulation is likely to be most effective) remained
unchanged after L-NMMA and did not change during head-up
tilt. These data, in contrast to previous observations after bolus
injection of L-NMMA (34), suggest that inhibition of tonic
production of NO does not alter dynamic cerebral autoregulation in humans.
We contend that these discrepancies are not likely to be an
artifact of differences in the pressure stimuli used in the present
and previous studies. First, under steady-state conditions, the
magnitudes of increases in mean arterial pressure in the supine
position after L-NMMA infusion are similar in the present and
previous studies (34). Second, the magnitude of hypotensive
stimuli induced by the thigh cuff release maneuver in previous
studies was only ⬃10 mmHg, which is well within the range of
spontaneous changes in arterial pressure observed in the
present study and reported by others (8, 14, 16, 21). Importantly, we demonstrated previously (36) that changes in CBF
velocity during transient hypotension induced by the thigh cuff
release maneuver could be predicted by the estimates of transAJP-Heart Circ Physiol • VOL

fer function between the spontaneous changes in arterial pressure and CBF velocity. However, direct comparisons between
the present and previous studies are difficult to make because
of the different regimens used for L-NMMA infusion and the
methods used for the quantification of dynamic cerebral autoregulation.
To reach the conclusions of the present study, several
important issues regarding the transfer function gain and phase
estimates must be addressed. First, we have considered that
transfer function gain at the higher frequencies (⬎0.20 Hz)
reflects mainly the impedance properties of the cerebrovascular
bed. In contrast, transfer function gain at the lower frequencies
likely reflects primarily the properties of dynamic cerebral
autoregulation (36). Thus the reduction of transfer function
gain at the high frequencies during tilt and after L-NMMA
observed in the present study likely reflect increased cerebrovascular impedance under these conditions.
Second, in the present study, normalized transfer function
gain during tilt was not calculated because of the uncertainty of
changes in intracranial pressure, thereby compromising the
estimates of cerebrovascular resistance under these conditions.
However, because the magnitudes of increases in steady-state
arterial pressure and changes in CBF velocity during tilt were
similar before and after L-NMMA, any confounding effect of
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Fig. 4. Group-averaged transfer function gain (A), phase (B), and coherence
function (C) in the supine position at baseline (solid line), after L-NMMA
infusion (dotted line), and after phenylephrine infusion (dashed line).

the cerebrovascular resistance on the estimation of transfer
function gain during tilt, if present, should be equivalent and
thus should have minimal effect on the conclusions of this
study.
Finally, we caution that with the small number of subjects
relative to the large variability of phase estimates, the possibility of a phase change at the low frequencies after L-NMMA
infusion cannot be excluded in the present study (Table 2).
However, we suggest that the following observations argue
against the possibility that L-NMMA has direct effects on the
phase relationship between the spontaneous changes in arterial
pressure and CBF velocity. First, the characteristics of spectral
distribution of phase estimates at coherence function ⬎0.5
were similar before and after L-NMMA both in the supine
position and during head-up tilt (Fig. 3). Second, although
there was a trend toward decreases in phase at the low frequencies after L-NMMA infusion, these changes were associated with significant increases in arterial pressure and similar to
those observed after phenylephrine infusion (Table 2). In
addition, the reduction in phase during tilt associated with
hypertensive stimuli did not change in the presence of LNMMA. Thus these data suggest that changes in phase with
L-NMMA, if they did occur, are more likely mediated by the
AJP-Heart Circ Physiol • VOL

increases in arterial pressure rather than direct effects of
L-NMMA on the phase estimates in the present study.
Study limitations. First, as with other studies in humans, the
major limitation of this study is the uncertainty of the degree
and the specificity of L-NMMA inhibition of NOS activity in
the cerebral circulation (5, 9). The loading dose and maintenance dose of L-NMMA used were chosen carefully and were
similar to the infusion regimen used by others, which documented sustained NOS inhibition in healthy humans (15, 20).
The significant pressor effects of L-NMMA observed in the
present study demonstrate the efficacy of NOS inhibition in the
systemic circulation. We therefore suggest that tonic endothelium NO production in the cerebral circulation was inhibited
similarly by systemic infusion of L-NMMA.
However, given the relatively small dose of L-NMMA used
in our human subjects, we are not certain that neuronal NO
released from the brain parenchyma and/or from the autonomic
nerves innervating the cerebral blood vessels was also inhibited
by systemic infusion of L-NMMA (5, 7, 27). At present, no
data are available to demonstrate that L-NMMA passes the
blood-brain barrier efficiently in humans. Thus the interpretation of the findings of the present study may be confounded by
the presence of neuronal NO as well as other vasoactive factors
interacting with the inhibition of endothelium NO in the
cerebral circulation (5). However, recent studies in animals
have demonstrated elegantly that it is the endothelium rather
than neuronal NO that plays an important role in the control of
resting CBF (2). Moreover, it has been shown that it is the
endothelium rather than neuronal NO that likely responds to
the biophysical signal of beat-to-beat changes in arterial pressure and/or flow and thus modulates vasomotor tone dynamically to maintain the stability of the systemic circulation (22, 23).
Second, because of uncertainties regarding changes in intracranial pressure during head-up tilt, we did not use phenylephrine infusion to account for the hypertensive effects of LNMMA infusion during tilt. However, it should be emphasized
that the primary purpose of head-up tilt in the present study
was to enhance arterial pressure variability and to determine
whether dynamic cerebral autoregulation would be altered by
L-NMMA infusion under these conditions. In addition, although arterial pressure measured at the heart level increased
during tilt, cerebral perfusion pressure may remain unchanged
or even be reduced associated with the reduction in hydrostatic
pressure during tilt (8, 21). Thus hypertensive effects of LNMMA infusion during tilt on the estimates of transfer function, if they did occur, should be similar to those observed in
the supine position with infusion of L-NMMA and phenylephrine.
In summary, with systemic infusion of L-NMMA sufficient
to increase arterial pressure significantly, we observed that
beat-to-beat arterial pressure and CBF velocity variability remained unchanged even when the magnitude of these oscillations was enhanced substantially during head-up tilt. Moreover, transfer function gain between the changes in arterial
pressure and CBF velocity at low frequencies persisted after
L-NMMA and did not change during tilt. These data provide
evidence that inhibition of tonic production of NO does not
appear to alter dynamic cerebral autoregulation in humans.
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